A Phase 1 interventional study of AZD6793 and AZD6793 Placebo in Type 2 Diabetes Mellitus, sponsored by AstraZeneca. Suspended at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-04-22.
Sponsored by AstraZeneca · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca — 13 open to participants now, 15 under way, 9 of them phase 3. Diabetes Mellitus, Type 2 · AstraZeneca.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, this one is the 228th largest by planned enrollment of the 280 interventional ones that give a count, is one of 14 that started in 2026, is one of 86 in phase 1, and was the 331st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →13 of the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Argentina, Brazil and 8 more countries
Ages 18+
AstraZeneca · Sites in China, Hong Kong, Malaysia and 2 more countries
Ages 18+
AstraZeneca · Sites in United States, Argentina, Australia and 13 more countries
Ages 18+
AstraZeneca · Sites in United States
Ages 18–55 · Healthy volunteers
AstraZeneca · Sites in United States, Australia, Bulgaria and 10 more countries
Ages 18+
By country, each count listing its studies:
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
345 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 89 · Phase 2 47 · Phase 3 122 · Phase 4 28
First in 2001; this study’s year is marked. 14 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 28 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 155 across the 280 interventional studies, 2,000 across the 65 observational. Of the 325 that completed or were terminated, 149 (46%) have results posted.
This tab as a report to print or save as PDF → With an account.
AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
5 of the studies in Diabetes Mellitus, Type 2 by AstraZeneca that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07723833AstraZenecaA Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants | 2026-11-18 |
| NCT07534592AstraZenecaA Study to Investigate the Effect of Elecoglipron on Rosuvastatin and Atorvastatin in Healthy Participants | 2027-01-25 |
| NCT07024823AstraZenecaA Study to Investigate Safety, Tolerability, PK, and PD of AZD4248 in Healthy Participants, Participants With CKD and Type 2 Diabetes, Assess Home Measurements of Creatinine in a Non-Interventional Cohort, and Assess the Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Participants | 2027-01-29 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
| NCT07606066AstraZenecaA Study to Identify and Characterize Patients With Type 2 Diabetes Mellitus for Possible Participation in Ongoing or Future Type 2 Diabetes Mellitus Clinical Studies | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 345 studies in Diabetes Mellitus, Type 2 by AstraZeneca, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to examine the effect of AZD6793 on the Pharmacokinetics and Pharmacodynamics of Metformin in Participants with Type 2 Diabetes Mellitus.
This is a double-blind, placebo-controlled, 2-period cross-over study conducted at a single study centre to assess the pharmacokinetics and pharmacodynamics (ie, glucose lowering effect) of metformin in participants with T2DM when metformin is administered alone and in combination with multiple doses of AZD6793. This study will consist of 2 treatment periods separated by a washout period of 7 to 14 days.
Approximately 28 eligible participants will be randomized to study intervention such that 24 evaluable participants complete the study (12 participants in each treatment sequence).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
AZD6793 and metformin
Drug: AZD6793
Placebo and metformin
Drug: AZD6793 Placebo
Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 (Treatment A).
Also known as: Active
Participants will receive oral doses of metformin with an interval of 12 hours between doses. The morning doses of metformin will be administered together with AZD6793 placebo (Treatment B).
Also known as: Placebo
Mean glucose levels
Mean glucose levels on Day 7 of each treatment period as assessed by Continuous Glucose Monitoring (CGM)
Time frame: Day 7
CGM Metric (Time in range)
The percentage of time (or hours/day) that blood glucose levels remain within a target
Time frame: Day 7 of each treatment period
CGM Metric (Time in tight range)
A metric measuring the percentage of time blood glucose remains between a pre-defined range.
Time frame: Day 7 of each treatment period
CGM Metric (time below range)
A metric representing the percentage of time and minutes per day spent with blood glucose below a certain range.
Time frame: Day 7 of each treatment period
CGM Metric (time above range)
A metric representing the percentage of time and minutes per day spent with blood glucose above a certain range.
Time frame: Day 7 of each treatment period
CGM Metric (AUC(0-24))
area under the concentration-time curve from time 0 to 24 hours postdose
Time frame: Day 7 of each treatment period
CGM Measure (Plasma fasting glucose)
A measure of glucose levels when a participant is in a fasting state.
Time frame: Day 7 of each treatment period
CGM Measure (AUC(0-4) after each meal)
area under the concentration-time curve from time 0 to 4 hours postdose after each meal
Time frame: Day 7 of each treatment period
CGM Measure (Total glucose AUC(0-24))
area under the concentration-time curve from time 0 to 24 hours postdose
Time frame: Day 7 of each treatment period
Metformin Plasma PK (AUC(0-12))
area under the concentration-time curve from time 0 to 12 hours postdose
Time frame: Day 7 of each treatment period
Metformin Plasma PK (Cmax)
maximum observed concentration
Time frame: Day 7 of each treatment period
Metformin Plasma PK (tmax)
time to reach maximum observed plasma concentration
Time frame: Day 7 of each treatment period
Metformin Plasma PK (t1/2λz)
Terminal elimination half-life
Time frame: Day 7 of each treatment period
Metformin Plasma PK (CL/F)
apparent total body clearance
Time frame: Day 7 of each treatment period
Metformin Plasma PK (Vz/F)
apparent volume of distribution during the terminal phase.
Time frame: Day 7 of each treatment period
Metformin Plasma PK (R AUC(0-12))
Ratio of test to reference based on AUC(0-12)
Time frame: Day 7 of each treatment period
Metformin Plasma PK (R Cmax)
Ratio of test to reference based on Cmax
Time frame: Day 7 of each treatment period
Metformin Urine PK (Ae(0-12))
cumulative amount excreted into the urine from time 0 to 12 hours postdose
Time frame: Day 7 of each treatment period
Metformin Urine PK (fe(0-12))
Percentage of dose excreted unchanged in urine from time zero to 12 hours post-dose
Time frame: Day 7 of each treatment period
Metformin Urine PK (CLR)
renal clearance from plasma
Time frame: Day 7 of each treatment period
AZD6793 plasma PK (AUC(0-24))
area under the concentration-time curve from time 0 to 24 hours postdose
Time frame: Days 1 through 7 of each treatment period
AZD6793 plasma PK (Cmax)
maximum observed concentration
Time frame: Days 1 through 7 of each treatment period
AZD6793 plasma PK (tmax)
time to reach maximum observed plasma concentration
Time frame: Days 1 through 7 of each treatment period
AZD6793 plasma PK (t1/2λz)
Terminal elimination half-life
Time frame: Days 1 through 7 of each treatment period
AZD6793 plasma PK (Ctrough)
concentration observed immediately prior to dosing
Time frame: Days 1 through 7 of each treatment period
AZD6793 plasma PK (Rac AUC(0-24))
accumulation ratio based on AUC(0-24)
Time frame: Days 1 through 7 of each treatment period
AZD6793 plasma PK (Rac Cmax)
Accumulation ration based on Cmax
Time frame: Days 1 through 7 of each treatment period
Started Jan 2026 (actual). Primary completion is estimated for Jun 2026, 5 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is suspended, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: AZD6793